Ser365
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser365  -  MOR-1 (human)

Site Information
SNIEQQNsTRIRQNt   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447783

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 , 2 ) , western blotting ( 1 , 2 )
Disease tissue studied:
breast cancer ( 2 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 , 2 ) , MEF (fibroblast) ( 1 ) , SKBr3 (breast cell) ( 2 )

Upstream Regulation
Treatments:
DAMGO ( 1 ) , EGF ( 2 ) , etorphine ( 1 ) , fentanyl ( 1 ) , morphine ( 1 )

Downstream Regulation
Effects of modification on MOR-1:
receptor internalization, altered ( 2 )

References 

1

Zheng H, et al. (2011) Modulating {micro}-Opioid Receptor Phosphorylation Switches Agonist-dependent Signaling as Reflected in PKC{epsilon} Activation and Dendritic Spine Stability. J Biol Chem 286, 12724-33
21292762   Curated Info

2

Chen Y, et al. (2008) EGF Transregulates Opioid Receptors through EGFR-mediated GRK2 Phosphorylation and Activation. Mol Biol Cell 19, 2973-83
18463167   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.